LENZ Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from LENZ Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 27% in 3 years, but profit fell: $1,745 less profit per $100 of extra sales. Lower than 97% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.9 times its market value (net cash). Higher than 97% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-142.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 86% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$1,745Sales grew 27% in 3 years, but profit fell: $1,745 less profit per $100 of extra sales.
Lower than 97% of Healthcare companies in United States.
Asset Productivity Ratio
+27% / +551%In 3 years sales changed by +27% while total assets changed by +551%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-148.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 88% of Healthcare companies in United States.
Cash Cushion Ratio
2.9× cashCash, after subtracting all debt, is 2.9 times its market value (net cash).
Higher than 97% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
LENZ Therapeutics, Inc. made a loss over the last year. LENZ Therapeutics, Inc. owes $0.07 for every $1 it owns. LENZ Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLENZ Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.47The share price is 0.47 times LENZ Therapeutics, Inc.'s book value per share, lower than 92% of Healthcare companies in United States.
Market cap
$102 MThe total market value of all of LENZ Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 65% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$219 MWhat LENZ Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.98Net worth divided by the number of shares. The share price of $3.25 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-59.2%LENZ Therapeutics, Inc. lost 59.2% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
Owes vs Owns
0.07×LENZ Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Dividend yield
NoneLENZ Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossLENZ Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-430.3%LENZ Therapeutics, Inc. lost $430 for every $100 of revenue.
Cash vs debt
Net cashLENZ Therapeutics, Inc. held $292 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For LENZ Therapeutics, Inc.: $102 M ÷ $219 M (30 Jun 2026) = 0.5.
What is LENZ Therapeutics, Inc.'s return on equity?
LENZ Therapeutics, Inc. lost 59.2% of its shareholders' money over the last year, lower than 57% of Healthcare companies in United States.
How much does LENZ Therapeutics, Inc. owe compared with what it owns?
LENZ Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Does LENZ Therapeutics, Inc. pay a dividend?
No. LENZ Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.